Darfur Refugees Seeing Things More Clearly, Thanks To Israeli Eye Initiative

When you mention Darfur refugees, most Israelis think about the hundreds of Sudanese who have streamed into Israel this year and the controversy and confusion over what the government should do with them.

However, Dr. Drora Zarfati, an ophthalmologist from the Emek Medical Center in Afula, sees the issue of refugees from Darfur in a different light, so to speak – she’s just returned from two weeks of performing dozens of eyesight restoring surgical procedures, and treating ocular diseases for south Sudanese refugees at the Kakuma refugee camp in northern Kenya.

“It’s unbelievably difficult conditions there,” Zarfati told ISRAEL21c, upon her return to Israel last week.

The Kakuma camp, located about 30 miles from the Sudanese border, houses over 75,000 people, mostly south Sudanese refugees, but also refugees from Ethiopia. The Center for International Cooperation (MASHAV) at the Israeli Ministry of Foreign Affairs, has been working in conjunction with the UN High Commission for Refugees (UNHCR) office in Nairobi to offer assistance to Sudanese refugees. Together, under the direction of Dr. Yossi Baratz, MASHAV’s medical projects coordinator in Africa, they set up a temporary eye clinic near the camp utilizing medical equipment purchased by MASHAV.

Baratz then recruited Zarfati and Dr. Nir Zaider from Rambam Hospital in Haifa to travel to the region to treat refugees with eye problems.

“This was actually my fourth mission for MASHAV – I had been in the past to Angola and Benin and really found it worthwhile. This year, they told me they had a really unique mission – at an eye camp for south Sudanese refugees from Darfur at a camp in northern Kenya,” she recalled.

Understanding that it would likely be a more harrowing and demanding trip than her previous endeavors, Tzarfati deliberated for a day and spoke with Baratz, who admitted the conditions wouldn’t be great. But he explained that the team would be staying at a UN compound near the refugee camp and the conditions would be “reasonable,” said Tzrafati.

“Ultimately, I couldn’t refuse this kind of mission. You can’t only go when it’s comfortable for you. The previous missions weren’t so easy, but I knew this one would be harder.”

In reality, Tzarfati found the mission much more difficult than she expected, but much more satisfying as well.

“The second night we were there, our quarters, which were provided by UNHCR, were flooded, and we had to evacuate in the middle of the night. Two assistants from the local hospital actually drowned in the floods, and the next day, when we returned, our rooms and all our belongings were wet and muddy,” she said. “That was quite an experience.”

But it paled in comparison to actual working conditions under which Tzarfati and Zaider performed.

“On a typical day, we would go to the hospital at the refugee camp, and there’d be no electricity. They’d have to find a generator, so meanwhile, we’d start checking patients with flashlights. No form of eye surgery had ever been performed at this clinic – the staff that assisted us had no knowledge of this kind of operation whatsoever, so that was quite a challenge.

“We would generally check about 60 to 80 patients a day who came from the camp. We would screen them and select those that needed surgery. And by 10 am, we would start operating for the day until the evening. The next morning, we’d check the recovering patients from the previous day and start over again. That basically repeated itself for the whole time we were there,” added Tzarfati.

All told, the two ophthalmologists checked and screened some 500 patients, mainly adults who had cataract problems, and performed dozens of operations. Zaider, an expert in an eyelid procedure which corrects what’s called ‘droopy’ eye, also performed a number of those operations.

On Sunday, when the local staff had the day off, Tzarfati and Zaidel visited the refugee camp themselves, met with some of the refugees and heard their stories which included descriptions of villages being burned and young children being killed.

“Even with their tragedy, the people gathered around us and thanked us for coming.
Some of them knew we were from Israel, and they said they were grateful to us,” she said.

Tzarfati, who studied medicine at Hadassah Medical Center and interned at Meir Hospital in Kfar Sava, chose ophthalmology for her specialty after taking it as an elective.

“I don’t regret it one bit,” she said.

She went to the US for a fellowship at Indiana University and studied with Professor Alon Harris, an expert in the field of glaucoma. And upon her return, she began her residency in the glaucoma clinic of Emek, where she still practices.

“I was exposed to MASHAV and their activities from a doctor in my department when I did my residency. He went on their behalf to conduct a clinic in Africa. When he got back, he was very enthusiastic about the experience, and I thought that if I got the chance later, it was something I wanted to do,” she said.

MASHAV has been conducting blindness prevention and eye-care missions in partner countries for many years – usually under the same model: two ophthalmologists at local hospitals or clinics. The team generally also trains the local personnel, and ophthalmologic equipment and supplies are donated by the Israeli government.

Despite her exhaustion upon returning home, Tzarfati said she’s willing to return to the clinic, or to another location where she’s needed. She hopes that the plight of the Sudanese refugees currently in limbo in Israel will soon be solved, and expressed a willingness to provide her own expertise, if needed.

“I’d be delighted to help the Darfur refugees who are in Israel. It’s ironic as on the one hand, the government sends us to help them there in Kenya, but here there’s some confusion about our policy. I hope there’ll be a decision on how we’re going to relate to this issue,” she said.

“But if I went thousands of miles to help them there, I would certainly and gladly do it here.”

israel21c

Using Stem Cells To Treat Damaged Eyes And A Rare Skin Disorder

Doctors and scientists in Italy have shown how stem cells can be used to treat damaged eyes and, in combination with gene therapy, a rare and debilitating skin disease.

Professor Michele De Luca of the University of Modena and Reggio Emilia described the work to an international meeting of stem cell scientists in Milan (“Challenges in Stem Cell Differentiation and Transplantation”) organised by the European Science Foundation’s EuroSTELLS stem cell programme in conjunction with the National Research Council of Italy.

Stem cell therapy involves the use of stem cells — ‘blank’ cells (‘toti- or ‘pluripotent’) that have not differentiated into specialised cells — to generate new tissues or organs. While widespread stem cell therapy lies some way in the future, Professor De Luca pointed out that it has been used already for many years in the treatment of burns. Many tissues of the body are continuously regenerated by their own population of stem cells. In the skin, such cells are called holoclones and for decades doctors have taken small samples of these cells from burns patients and cultured the cells into new skin that can be grafted onto the wound.

Professor De Luca’s team showed that cells of the transparent outer covering of the eye, the cornea, are constantly being replaced by new cells deriving from an area surrounding the cornea called the limbus. The cells differentiate into corneal epithelium and migrate to the cornea.

“If the cornea is damaged severely by a chemical burn or infection, for example, it can become opaque and necessitates a transplant,” Professor De Luca told the meeting. “However, a transplant will only be successful if the patient’s limbus has remained intact so that it can continue to replenish the new cornea.”

For many years doctors did not understand why some transplants failed — because they did not appreciate the requirement for the limbus.

In cases where the limbus is destroyed there has been little hope to restore the patient’s sight. Professor De Luca’s team decided to take a leaf from the way that burns are treated and grow a new cornea from limbar stem cells taken from the healthy eye.

By removing a small sample of these cells it was possible to culture a new cornea and graft it on to the damaged eye. The team showed that of 240 patients who were operated on in this way, the cornea regenerated successfully in 70% of cases.

The researchers then turned their attention to a rare but debilitating genetic disease of the skin resulting in a syndrome known as Epidermolysis Bullosa, in which the skin is highly fragile and prone to blistering due to faulty proteins that effectively anchor the surface layers of skin to the body.

In one form of the disease there is a mutation in one of these anchoring proteins called laminin 5. The Italian researchers obtained consent to carry out a small-scale trial of a novel gene therapy using skin holoclones on one patient, a 37-year-old male, on small part of his body .

“Because the patient’s body was so badly affected it was difficult to isolate any stem cells from his skin,” Professor De Luca told the conference. “Most people have between seven and ten per cent of holoclones. Our man had none. Eventually we found a few in the palms of his hand and cultured them from a biopsy.”

The team then used gene therapy to insert the correct laminin gene into the growing cells and grafted the new tissue onto the patient’s body. The graft was successful and after several months the skin remained to all intents normal, without the blistering and flaking.

“This demonstrates that it is possible to use stem cells in gene therapy for genetic skin disorders,” Professor De Luca said.

EuroSTELLS is the European Collaborative Research (EUROCORES) programme on “Development of a Stem Cell Tool Box” run by the European Medical Research Councils (EMRC) Unit in the European Science Foundation. ESF provides scientific coordination and support for the networking activities of funded scientists through the EC FP6 Programme, under contract no. ERAS-CT-2003-980409. Research funding is provided by the participating national organisations.

Source: Sofia Valleley

European Science Foundation

Opening Of New Cambridge Eye Unit, UK

A new unit for eye patients is to officially open at Addenbrooke’s Hospital.

The Cambridge Eye Unit boasts state-of-the art facilities and is double the size of the previous eye surgery facility. The unit is the leading centre for specialist eye surgery in the Eastern region, with two operating theatres and a 10-bed ward.

Most patients coming through the unit are having cataract surgery about 1,500 corrective procedures are carried out annually. However, more specialist work, such as glaucoma surgery, eye lid plastic surgery, surgery for watery eyes and children’s eye surgery, also take place.

The unit has been purpose-built for patients with visual-impairment and located next to the cateract clinic, where patients are assessed before surgery.

Karen White, from Bourn, has been a regular visitor to the eye unit with Ella, her three-year-old daughter. Ella was a premature baby and needed laser eye surgery to combat Retinopathy of Prematurity – a potentially blinding disease.

Mrs White said: “The work they do in the unit is outstanding. Ella was six weeks at the time and weighed only two pounds but the staff were amazing and the operation has proved a success.
“I look forward to visiting the new unit. The standard of the facilities will now match the first-class care.”

The unit will be officially opened on Tuesday 24th March at 10am. John Scott, former Consultant Vitreo-retinal Surgeon at Addenbrooke’s, will unveil a commemorative plaque and guests, including Ella and Karen, will be given a tour.

Louise Allen, Consultant Paediatric Ophthalmologist and Clinical Director of Ophthalmology, said: “The unit provides a streamlined service for patients, who will benefit from the latest technology and a dedicated team of staff in a comfortable and purpose-built environment.”

Source
Cambridge Eye Unit

View drug information on ella.

Dr. Eli Peli Of Schepens Eye Research Institute Elected SPIE Fellow

The International Society for Optical Engineering will honor 56 new Fellows of the Society this year. Fellows are members of distinction who have made significant scientific and technical contributions in the multidisciplinary fields of optics, photonics, and imaging. They are honored for their technical achievement, for their service to the general optics community, and to SPIE in particular. More than 480 SPIE members have become Fellows since the Society’s inception in 1955.

“The annual recognition of Fellows provides an opportunity for us to acknowledge outstanding members for their service to the general optics community,” says Brian Culshaw, SPIE President.

Eli Peli Schepens Eye Research Institute, Department of Ophthalmology, Harvard Medical School, USA, for specific achievements in image understanding and perception, visual psychophysics, and physiological optics for the visually impaired.

Peli has done significant basic and applied research towards enhancing imagery for the visually impaired. His work has led to significant pioneering work in digital image processing of retinal images in the 1980s. He was one of the first researchers to apply digital image processing to analysis of nerve fiber layer in Glaucoma and for the measurement of drusen and their changes in age related macular degeneration or AMD. His work on electronic and optical devices for impaired vision has led to several products on the market as well as many novel approaches for testing the effects of vision enhancement and image quality.

Peli’s service to the optics community is impressive. He has supported numerous workshops, advisory panels and committees relative to impaired vision as well as modeling of normal vision. He has also worked with the National Institute of Health on the development of public information and education. His service to SPIE includes chairing sessions relating to visual representation and processing, presenting a continuing education seminar on vision models for simulation and image quality metrics, and serving on the technical committee of visual communications and image processing.

SPIE – The International Society for Optical Engineering is dedicated to advancing scientific research and engineering applications of optical, photonic, imaging, and optoelectronic technologies through its meetings, education programs, and publications. For more information, visit our website at spie/

Contact: Patti Jacobs

Schepens Eye Research Institute

UK Government spin on success of NHS cataract privatisation criticised

Patricia Hewitt, the UK’s Secretary of State for Health, is wrong to announce that independent sector-treatment centers (IS-TCs) reduced waiting times for cataract operations, states the author of a correspondence letter in this week’s issue of The Lancet.

Patricia Hewitt recently announced to the Fabian Society that “the first wave of IS-TCs has already brought down the waiting times for cataract operations to three months, a target achieved four years earlier than promised”. However, ophthalmic surgeon Simon Kelly states that it is the National Health Service (NHS) ophthalmic staff and not the IS-TCs that have delivered improved services to English cataract patients. The letter follows the recent Lancet editorial, (Lancet 2005; 366:1293), which called for the UK government’s programme of wide-ranging privatisation of the NHS to be stopped until there is independent evidence on the effect of the policy.

Kelly states that targeted capital to construct new NHS ophthalmic facilities and improved practice arising from Action on Cataracts (an NHS scheme run along with the Royal College of Ophthalmologists) not IS-TCs increased the rate of cataract surgery from 170,000 operations in 1998/99 to over 300,000 operations per year by 2003/04. He also notes that the South African corporation Netcare, which won the bid for the Government’s mobile cataract IS-TC scheme, will have to be paid for over 44 000 cataract operations in contracts arranged over 5 years, irrespective of whether they are needed or even carried out.

Mr Kelly (Bolton Eye Unit, Bolton Hospitals NHS Trust, UK) comments: “It is not the IS-TCs that have delivered improved services to English cataract patients, it is National Health Service (NHS) ophthalmic staff�The Lancet is correct to call for a robust analysis of IS-TC evidence and dismiss spin.”

The Royal College of Ophthalmologists have produced a statement in response to this letter. Please visit rcophth.ac

Joe Santangelo
j.santangeloelsevier
Lancet
thelancet

Can Poor Vision Or Hearing Affect Your Mind?

Loss of acuity in hearing and vision is a common accompaniment to aging. While only an estimated one in every 1,000 people under the age of 45 has visual impairment, one in every 13 people over the age of 65 does, according to the American Foundation for the Blind. Hearing suffers a similar decline: among people aged 65 to 74, 23 percent have trouble hearing; after age 75, the figure climbs to nearly 40 percent.

In addition to weakening important connections to the environment, this often gradual onset of sensory deprivation can have other important effects on the brain. It is associated with the development of mood disorders, and with declines in key aspects of mental functioning. Finding ways to prevent sensory change, and to adjust to impairments if they develop, is important to maintaining mental health as we age, according to Massachusetts General Hospital’s Mind, Mood & Memory.

“Vision and hearing loss are major public health issues because they affect so many older individuals, and because they have an adverse impact on mental health,” says Dennis Norman EdD, Chief of Psychology at Massachusetts General Hospital. “If the senses are limited, everything is affected, including interaction with surroundings, relationships, activities, and feelings of self-worth. Impairment can lead to depression, anxiety, social isolation and many other problems.”

WHEN SENSES DECLINE

Visual impairment is defined by the U.S. Centers for Disease Control and Prevention as blindness in one eye, blindness in both eyes, or any other significant trouble seeing. Hearing impairment is defined as deafness in one ear, deafness in both ears, or any other significant trouble hearing. According to CDC figures, an estimated 3.6 million Americans aged 70 or over suffer from some form of visual impairment, while 6.7 million older adults report hearing impairment. An estimated 1.7 million adults aged 70 and over report both vision and hearing impairment.

These older people with sensory deficits are at greater risk for a variety of health problems, according to a recent CDC survey. Compared to older individuals without impairments, those with sensory impairment are significantly more likely to encounter functional problems such as difficulties in walking, getting outside, getting into or out of a bed or chair, or managing medications. They are more vulnerable to falls, hypertension, heart disease, stroke, and depression. Those with visual impairment are also less likely to socialize than individuals without sensory impairment.

“That’s why evaluating vision and hearing should be part of any health checkup,” Dr. Norman says. “It’s important to catch subtle changes, because the earlier you treat them, the better people are able to deal with the impairments.”

MOOD EFFECTS

People with vision and hearing problems are also more vulnerable to depression and anxiety, and are less likely to engage in social activities. Depression is characterized by a low mood lasting two weeks or more with symptoms such as pervasive sadness, loss of interest in activities usually enjoyed, feelings of worthlessness, changes in appetite and sleep patterns, agitation, fatigue, and suicidal thought.

A study presented at the International Congress Series in London in April 2005 found that among a group of people with seriously impaired vision, 22 percent exhibited signs of major depression. A National Council on Aging study of 2,300 people with hearing loss found that among individuals with untreated impairment, up to 30 percent reported major depression, and up to 17 percent reported suffering anxiety for a month or more in the preceding year. Mood disorders associated with sensory impairments were often significantly improved through rehabilitation training and/or the use of assistive devices such as hearing aids.

COGNITION EFFECTS

Research suggests that cognition and memory, too, can suffer when vision and hearing fade, although the precise reasons for these changes are not clear. A study of 2,946 people with age-related macular degeneration (AMD, a condition in which a key area of the retina degenerates and people lose the ability to see objects in detail) uncovered a strong link between visual problems and cognitive impairment. From 2000 to 2004, researchers measured the degree of visual impairment of each subject, then administered a series of six tests designed to measure thinking, learning and memory abilities. They found subjects with the greatest degree of visual impairment had the poorest average scores on the test of cognition, and that scores decreased as vision decreased, according to a report in the April 2006 issue of Archives of Ophthalmology. The authors proposed that AMD and cognitive decline may result from common risk factors; or that visual impairment may cause cognitive impairment by reducing people’s participation in stimulating events; or that impairment may cause depression and isolation, which may then lead to cognitive decline.

People with hearing impairment may also experience problems with cognitive functioning. Work by researchers at Brandeis University suggests that memory ability among people with hearing loss may be compromised by the extra effort required to hear. In a study comparing a group of older people with mild-to-moderate hearing impairment with a similar group without hearing impairment, participants were read a list of 15 words and instructed to remember only the last three words. People with hearing impairments were able to remember the final word as well as the unimpaired, but they did significantly worse at remembering the other two words. Differences between the two groups may indicate that resources that would otherwise be available for higher-level comprehension or encoding information in memory was expended by the hearing-impaired in the effort to hear accurately, the researchers suggested.

PREVENTING SENSORY CHANGES

Make an effort to prevent hearing and vision loss by getting regular checkups to catch problems early, and by taking preventative measures such as these:

Protect your eyes by wearing sunglasses to reduce exposure to ultraviolet radiation (UV) that might damage the eyes; use eye protection when operating machinery that may inflict injury from flying objects such as sparks or chips.

Protect your ears from loud noises (85 decibels or more) that can damage the delicate hair cells of the inner ear by avoiding noise sources, using earplugs or keeping earphone volume low.

Maintain health by getting regular medical checkups, giving up smoking, and managing conditions such as diabetes and high blood pressure that can damage eyes and/or ears.

Eat right: A healthy diet can protect your eyes. Consume plenty of citrus fruits and juices for vitamin C; eat carrots and dark-green leafy vegetables such as spinach for beta-carotene; eat whole grains, nuts, and eggs for vitamin E; and get needed zinc from fish, meats, whole grains and dairy products. For nutrients that strengthen or protect hearing, eat foods rich in: vitamin D (fortified dairy products, seafood, fortified cereals); vitamin B12 (meat, poultry, eggs, dairy products and shellfish); and folate (liver, eggs, beans, fortified cereals, leafy green vegetables, and fruits).

Consider supplements. Ask your doctor about taking supplements. In addition to the vitamins and minerals mentioned above, supplements of bilberry (huckleberry) have been thought to perhaps help protect eyesight, and ginkgo biloba and vinpocetine may help prevent or ameliorate hearing problems.
There are also basic steps that can be taken to help people cope with existing impairment of hearing and vision.

“Recognize the fact that you or a loved one may need assistance,” advises Dr. Norman. “Try to accept help from others, and take advantage of devices such as magnifying lenses and hearing aids that can help ensure independence.”

WHAT YOU CAN DO

Get professional help for mood disorders such as anxiety and depression.
Make an effort to continue social activities. Isolation can lead to depression and lack of mental stimulation.

Learn about the impairment, and how other people cope with it. Consider joining a support group.

HELPFUL RESOURCES

These groups that offer support and information to help people cope with hearing and vision impairment

Visit, eyecareamerica

Belvoir Media Group, LLC.
7820 Holiday Drive So., Suite 315
Sarasota, FL 34231
United States
belvoir

Health Minister Announces New Programme To Speed Up Eye Treatment, Wales

Nine treatment centres will be established across Wales to help ensure faster, fairer treatment for patients at risk of losing their sight, Health Minister Edwina Hart announced today. It follows a review of current arrangements by Local Health Boards for delivering treatment for wet age-related macular degeneration (AMD). Wet AMD is the primary cause of sight loss in the UK.

Last June, Mrs Hart announced that the NHS in Wales would fund Lucentis treatment for first and second eye patients with wet AMD.

Mrs Hart also announced a further ??10m for providing treatment for wet AMD in 2009/10. ??5m is already being made available for treatment in 2008/09.
Edwina Hart said:
“Since the summer, when I announced that the Assembly Government would fund treatment for wet AMD in both eyes, it has become clear that there are differences in service delivery across Wales. To ensure that every patient is guaranteed the same quality of care, nine treatment centres will be established across Wales. Funding treatment for both eyes will mean added pressure on ophthalmology services. I am therefore pleased to announce that staffing levels will also be increased this month.

“An ophthalmology network will also be established so that, in the longer term, there is a vehicle for clinical training and expertise in the field of wet AMD. All this will ensure we provide a faster, fairer, higher quality service for patients.”

Patients in Wales are already undergoing treatment for wet AMD in the second eye. Treatment for wet AMD in the first eye will commence from 20 November.
Mrs Hart also said that patients who have self-funded treatment for wet AMD will be allowed to transfer their treatment with future costs being met by the Welsh Assembly Government.

1. The nine treatment centres will be located at:

North Wales:
— Ysbyty Gwynedd
— H M Stanley, St. Asaph
— Wrexham Maelor

West Wales:
— Bronglais, Aberystwyth
— Amman Valley, Ammanford
— Singleton

South East Wales:
— Royal Glamorgan
— University Hospital, Cardiff
— St. Woolos, Newport

With the exception of Amman Valley, which is a new treatment centre, all the other locations are hospital based and are already treating patients.

2. On 24 June 2008, the Health Minister made a written statement announcing that the NHS in Wales would fund Lucentis treatment for first and second eye patients with Wet Age-Related Macular Degeneration, to the tune of ??5m for 207/08.

3. On 14 July 2008, the Health Minister made a further written statement announcing that Chris Martin, Chair of Pembrokeshire LHB, would assess how the care of patients with wet AMD would be delivered across Wales.

Health Minister (Wales) Edwina Hart

View drug information on Lucentis.

Ampio Pharmaceuticals Announces Initiation Of Phase II Clinical Trial Of Optina™

Ampio Pharmaceuticals, Inc. (OTC Bulletin Board: AMPE) announced the initiation of a Phase II clinical trial of Optina™ for the treatment of diabetic macular edema, an early stage of diabetic retinopathy. Diabetic macular edema is responsible for most vision loss in patients with diabetes mellitus.

Ampio Pharmaceuticals has completed a formal agreement with St Michael’s Hospital, Toronto, Canada as a final step for ethics board approval which is expected in the next few days. “We are very excited to be commencing this trial and pending the final approval of the ethics board we will commence patient recruitment in the next weeks,” stated Don Wingerter, CEO of Ampio Pharmaceuticals. Chief Scientific Officer, Dr. David Bar-Or added, “After accumulating in vitro and animal data, it is gratifying to begin treating patients for this debilitating disease.”

Diabetic macular edema and diabetic retinopathy are complications of diabetes mellitus that occur in approximately one third of patients 10 years after the onset of diabetes and are rapidly growing causes of blindness worldwide. There is currently no effective oral medication to treat diabetic macular edema or diabetic retinopathy. Optina™ is a repurposed oral drug with an established human safety profile. Pre-clinical studies have shown the potential for Optina™ to significantly reduce diabetic macular edema in patients.

About Ampio Pharmaceuticals

Ampio Pharmaceuticals, Inc. develops innovative proprietary drugs for metabolic disease, eye disease, kidney disease, inflammation and CNS disease. The product pipeline includes new uses for previously approved drugs and new molecular entities (“NMEs”). By concentrating on development of new uses for previously approved drugs, approval timelines, costs and risk of clinical failure are reduced because these drugs have strong potential to be safe and effective while their shorter development times can significantly increase near-term value. A key strategy includes actively exploring partnership, licensing and other collaboration opportunities to maximize Ampio’s product development programs.

Safe Harbor Statement

Certain of the above statements contained in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements are within the meaning of that term in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those indicated in the forward-looking statements as a result of various factors.

Source: Ampio Pharmaceuticals, Inc

Strong International Presence And High Attendance Mark American Academy Of Ophthalmology Joint Meeting

Turnout was strong for the largest and most comprehensive ophthalmic educational meeting in the world, the 2009 American Academy of Ophthalmology (Academy)-Pan-American Association of Ophthalmology (PAAO) Joint Meeting, held in San Francisco Oct. 25 to Oct. 27. Preliminary figures for attendance at the meeting were approximately 25,000, a 17 percent increase over 2008. More than 6,000 international physicians attended the meeting, an increase of 50 percent compared to 2008. Preliminary figures for attendance at the Subspecialty Day events Oct. 23 and 24 also showed a strong increase, totaling more than 7,100, a 37 percent rise over the previous year.

“That 25,000 people from all fifty states came to the meeting in the midst of economic turmoil speaks volumes about the appetite of ophthalmologists for the latest knowledge and skills,” said David W. Parke II, MD, executive vice president and CEO of the Academy. “The presence of so many of our international colleagues was especially gratifying and enriched the meeting even more. Our patients come first, and we all recognize that providing the highest quality care means committing to continual education.”

The opening session on Oct. 25 included the presentation of the 2009 Laureate Recognition Award, the Academy’s highest honor, to Bernard Becker, MD, for his leadership in ophthalmic research, clinical care, and education. In addition, the session featured a tribute to H. Dunbar Hoskins Jr., MD, who retired as the Academy’s executive vice president in March, 2009 after 16 years.

Science highlights from the media included research about a wide range of ophthalmic issues, including the vision of Iraqi war veterans, barriers to care among glaucoma patients, and complaints about vision changes as an early clue to Alzheimer’s. A full listing of highlights is available in the Academy’s Joint Meeting Newsroom.

Press briefings at the Joint Meeting included presentations on advances in cataract surgery and intraocular lenses and a panel on key issues to emerge during the year, including advances in diabetic retinopathy, the relationship between learning disabilities and vision, and advances in management of dry age-related macular degeneration. Audio recordings of these brief briefings are also available on the Academy’s Web site.

Source
American Academy of Ophthalmology

Blocking neurodegeneration by radiation and bone marrow transfer prevents inherited glaucoma in mice

In a discovery that could point to new treatments for a wide range of neurodegenerative diseases, Jackson Laboratory
researchers have found that high-dose radiation and bone marrow transfer treatments on glaucoma-susceptible mice completely
blocked the development of glaucoma, by preventing neurodegeneration.

Glaucomas are among the most common neurodegenerative diseases, and a leading cause of blindness in the United States. Many
patients with glaucoma have high intraocular pressure (IOP), long believed to be a cause of the degeneration of the optic
nerve and nerve cells in the retina that leads to vision loss. The standard treatment for glaucoma is reducing the
intraocular pressure by medication or surgery.

However, researchers have also observed that some patients with elevated IOP do not develop optic nerve and retinal damage,
while others do incur damage despite relatively normal IOP. “It’s increasingly clear,” says Dr. Simon W.M. John, leader of
the Jackson Laboratory research team and a Howard Hughes Medical Institute Investigator, “that multiple mechanisms are at
work in this disease.”

John and researchers elsewhere have identified several genes associated with glaucomas. They have also developed inherited
mouse glaucoma models that reliably develop glaucoma in mid-life. One of these models is the DBA/2J mouse.

The Jackson research team treated 5- to 8-week-old DBA/2J mice with a single, high dose of gamma radiation, together with
bone marrow transfer.

When they examined the mice at 12-14 months–an age at which most DBA/2J mice have advanced glaucoma–the researchers were
amazed to find that the vast majority of mice did not have glaucoma. There was no detectable loss of the retinal ganglion
cells, which typically degenerate in glaucoma.

“It was very surprising and we had to be very careful,” John said. “We repeated the experiment two more times with the same
results.”

The research paper, published online in the Proceedings of the National Academy of Sciences, is the first to suggest that
high-dose radiation together with bone marrow transfer–treatments in use today for human patients with leukemia and other
cancers–could potentially treat glaucoma.

“It is possible that the treatment may also protect against other neurodegenerative diseases, but many experiments are needed
to test this,” he noted. Conditions in this category include Alzheimer’s disease and Parkinson’s disease.

Of course, full-body radiation and bone marrow transfer is not an appropriate therapy for human glaucoma. Dr. John said his
lab would be investigating whether directing radiation locally to the optic nerve and retina might be equally effective in
preventing glaucoma in mice. Ultimately, studies that reveal how the treatment works may lead to new types of therapy for
people.

The Jackson Laboratory, founded 75 years ago, is the world’s largest mammalian genetics research institution. Its research
staff of more than 450 investigates the genetic basis of cancers, heart disease, osteoporosis, Alzheimer’s disease, glaucoma,
diabetes, and many other human diseases and disorders. The Laboratory is also the world’s source for nearly 3,000 strains of
genetically defined mice, home of the Mouse Genome Database and many other publicly available information resources, and an
international hub for scientific courses, conferences, training and education.

High-dose radiation with bone marrow transfer prevents neurodegeneration in an inherited glaucoma. Michael G. Anderson,
Richard T. Libby, Douglas B. Gould, Richard S. Smith, and Simon W. M. John. Proceedings of the National Academy of Sciences,
online publication March 9, 2005.

Contact: Joyce Peterson
joycejax
207-288-6058
Jackson Laboratory
jax